941 F.3d 1149
Fed. Cir.2019Background
- Idenix sued Gilead for infringement of U.S. Patent No. 7,608,597 (’597), which claims a method of treating HCV by administering β-D-2'-methyl-ribofuranosyl nucleosides (claim requires 2'-methyl-up and non-hydrogen substituents at 2'-down and 3'-down; preamble limits to compounds effective to treat HCV).
- District court adopted a broad claim construction (allowing many non-hydrogen substituents at 2'-down), Gilead stipulated infringement under that construction, and trial proceeded on invalidity (written description and enablement).
- Jury found the asserted claims valid and awarded damages; Gilead renewed JMOL on enablement and written description—district court granted JMOL of invalidity for lack of enablement but denied JMOL on written description.
- Federal Circuit (majority) affirmed the JMOL ruling that the ’597 patent is not enabled: the specification covers billions/millions/thousands of potential 2'-methyl-up nucleosides, the art is unpredictable, and practicing the full scope would require undue synthesis-and-screening.
- The panel also reversed the district court’s denial on written description, holding the specification lacks blaze marks for species such as the 2'-methyl-up/2'-fluoro-down nucleoside in Gilead’s accused product; hence the patent fails the written-description requirement.
- Judge Newman dissented, arguing a reasonable jury could have read the claims narrowly to the specifically described/synthesized/assayed compounds and that the majority improperly invalidates claims based on unclaimed variants in the specification.
Issues
| Issue | Plaintiff's Argument (Idenix) | Defendant's Argument (Gilead) | Held |
|---|---|---|---|
| Enablement under §112 (undue experimentation) | POSA would focus on a narrow, predictable subset (guided by specification, target NS5B, working examples); synthesis/screening of candidates is routine | Claims cover at least "many, many thousands" (if not millions/billions) of 2'-methyl-up nucleosides; art is unpredictable; would require extensive synthesis and screening -> undue experimentation | Court: Not enabled. JMOL for Gilead affirmed: practicing full scope requires undue experimentation (Wyeth controlling). |
| Written-description under §112 (possession of claimed genus/species) | Specification provides formulas, working examples, synthesis routes and target; these serve as blaze marks to support the genus | Spec does not disclose (or give blaze marks to) many species claimed—notably 2'-methyl-up/2'-fluoro-down; examples are narrow and don’t explain why other variants would work | Court: Written description inadequate. Denial of JMOL reversed and claim invalid for lack of written description. |
| Overturning jury via JMOL (standard of review) | Jury verdict should stand; there was expert testimony that supports enablement/description | No reasonable jury could have found enablement/written description given the undisputed breadth and unpredictability; JMOL appropriate | Court: Applied Third Circuit JMOL standard; concluded no reasonable jury could find enablement (affirmed) and reversed district court on written description. |
Key Cases Cited
- In re Wands, 858 F.2d 731 (Fed. Cir. 1988) (Wands factors for assessing undue experimentation)
- Wyeth & Cordis Corp. v. Abbott Labs., 720 F.3d 1380 (Fed. Cir. 2013) (claim covering millions of variants held not enabled where many candidates required synthesis and screening)
- Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (written-description requirement; inventor must show possession of claimed invention)
- Genentech, Inc. v. Novo Nordisk A/S, 108 F.3d 1361 (Fed. Cir. 1997) (specification, not POSA knowledge, must supply novel aspects for enablement)
- ALZA Corp. v. Andrx Pharm., LLC, 603 F.3d 935 (Fed. Cir. 2010) (disclosure that merely points to further research is non-enabling)
- Enzo Life Scis., Inc. v. Roche Molecular Sys., Inc., 928 F.3d 1340 (Fed. Cir. 2019) (narrow working examples insufficient to enable broad claims in unpredictable art)
- Bos. Sci. Corp. v. Johnson & Johnson, 647 F.3d 1353 (Fed. Cir. 2011) (chemical genus requires precise definition or representative species)
- Storer v. Clark, 860 F.3d 1340 (Fed. Cir. 2017) (prior Idenix-related decision concerning 2'-methyl-up/2'-fluoro-down species)
- In re Hyatt, 708 F.2d 712 (Fed. Cir. 1983) (enablement must be commensurate in scope with the claim)